Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

Inclusion Criteria: * age 18 years or older, gender not limited; * A definite diagnosis of Leptomeningeal metastases from lung cancer, including cerebrospinal fluid cytology and/or neuroimaging; * Have a clear history of lung cancer, including histopathological diagnosis, or cytopathology combined with imaging diagnosis * Patients who received any of EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib etc.) meet the diagnostic criteria for secondary resistance and were in a slow progression stage * Detection results of cerebrospinal fluid, blood gene or lung tissue specimens showed EGFR mutation, and immunohistochemistry results of cerebrospinal fluid, blood gene or lung tissue showed positive EGFR expression * Bone marrow, liver, kidneys and blood clotting function are relatively stable Exclusion Criteria: * Eastern Cooperative Oncology Group scored \> 2 points * Patients had poor compliance, or for other reasons the investigator considered them unsuitable to participate in the study